Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol crossover study on lung hyperinflation and breathlessness in COPD
2007-004684-22Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoints: Isotime exercise inspiratory capacity, Peak exercise inspiratory capacity and 9 more. Started Nov 2007; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2007-004684-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004684-22.